Get the Stockscreener App
75.25
0.27%
-0.20
After Hours:
75.25
Ionis Pharmaceuticals Inc stock is traded at $75.25, with a volume of 850.25K.
It is down -0.27% in the last 24 hours and up +0.62% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
See More
Previous Close:
$75.45
Open:
$75.84
24h Volume:
850.25K
Relative Volume:
0.40
Market Cap:
$12.44B
Revenue:
$1.06B
Net Income/Loss:
$-326.58M
P/E Ratio:
-35.80
EPS:
-2.1022
Net Cash Flow:
$-977.73M
1W Performance:
+4.83%
1M Performance:
+0.62%
6M Performance:
+0.76%
1Y Performance:
+123.66%
1-Day Range:
$74.82
$76.96
1-Week Range:
$71.30
$77.76
52-Week Range:
$31.66
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
75.25 | 12.47B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
MSN Money - MSN
Form 144: Option exercises listed; Joseph Loscalzo sold shares (IONS) - Stock Titan
Ionis well-positioned for continued momentum and substantial valu - The National Law Review
Ionis to host 2026 virtual Annual Meeting of Stockholders - BioSpace
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market - openPR.com
Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com
Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks - TipRanks
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Discipline and Rules-Based Execution in IONS Response - Stock Traders Daily
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
VY(R) T. Rowe Price Diversified Mid Cap Growth Portfolio's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Teladoc (TDOC) - The Globe and Mail
Ionis Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Ionis to present at upcoming investor conferences - The National Law Review
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold - Moomoo
Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Ionis Pharmaceuticals (IONS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
IONS Maintained by Barclays -- Price Target Raised to $115 - GuruFocus
Atle Fund Management AB's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus
Ionis Pharmaceuticals Projects Ozarsen Sales Exceeding 3 Billion Dollars - HarianBasis.co
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com
Narrow-Moat Ionis' Peak Sales Raised for Olezarsen; Positive Outlook as Late-Stage Assets Advance - Morningstar
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
IONS Maintained by RBC Capital -- Price Target Raised to $100 - GuruFocus
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating - marketscreener.com
Vanguard reports 5.05% stake in Ionis Pharmaceuticals (NASDAQ: IONS) - Stock Titan
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View - TradingView
Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $86 - Moomoo
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $100 to $125 - Moomoo
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals Q1 2026 earnings preview - MSN
IONS Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - GuruFocus
Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity By Investing.com - Investing.com India
IONS SWOT Analysis: Strong Revenue Growth Amidst Challenges Reve - GuruFocus
Ionis Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IONS) 2026-04-29 - Seeking Alpha
Oppenheimer raises Ionis Pharmaceuticals price target on guidance By Investing.com - Investing.com Canada
Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity - Investing.com
Ionis outlines 2026 revenue of $875M-$900M while lifting olezarsen peak sales view to >$3B - MSN
Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Ionis Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c) - TipRanks
Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Quarterly Earnings Results - MarketBeat
Ionis gains on late-stage trial win for hypertriglyceridemia therapy - MSN
Ionis Pharmaceuticals Q1: Revenue $246.1M, EPS (loss) $0.56 — 10-Q Summary - TradingView
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):